Details

Autor(en) / Beteiligte

• Hatzipanagiotou, Maria Eleni
• Pigerl, Miriam
• Gerken, Michael
• Räpple, Sophie
• Zeltner, Verena
• Hetterich, Madeleine
• Ugocsai, Peter
• Fernandez-Pacheco, Miriam
• Inwald, Elisabeth Christine
• Klinkhammer-Schalke, Monika
• Ortmann, Olaf
• Seitz, Stephan

Titel

Does timing of neoadjuvant chemotherapy influence the prognosis in patients with early triple negative breast cancer?

Ist Teil von

• Journal of cancer research and clinical oncology, 2023-10, Vol.149 (13), p.11941-11950

Ort / Verlag

Berlin/Heidelberg: Springer Berlin Heidelberg

Erscheinungsjahr

2023

Quelle

SpringerLink (Online service)

Beschreibungen/Notizen

• Purpose For patients with triple negative breast cancer (TNBC), the optimal time to initiate neoadjuvant chemotherapy (TTNC) is unknown. This study evaluates the association between TTNC and survival in patients with early TNBC. Methods A retrospective study using data from of a cohort of TNBC patients diagnosed between January 1, 2010 to December 31, 2018 registered in the Tumor Centre Regensburg was performed. Data included demographics, pathology, treatment, recurrence, and survival. Interval to treatment was defined as days from pathology diagnosis of TNBC to first dose of neoadjuvant chemotherapy (NACT). The Kaplan–Meier and Cox regression methods were used to evaluate the impact of TTNC on overall survival (OS) and 5 year OS. Results A total of 270 patients were included. Median follow up was 3.5 years. The 5-year OS estimates according to TTNC were 77.4%, 66.9%, 82.3%, 80.6%, 88.3%, 58.3%, 71.1% and 66.7% in patients who received NACT within 0–14, 15–21, 22–28, 29–35, 36–42, 43–49, 50–56 and > 56 days after diagnosis. Patients who received systemic therapy early had the highest estimated mean OS of 8.4 years, while patients who received systemic therapy after more than 56 days survived an estimated 3.3 years. Conclusion The optimal time interval between diagnosis and NACT remains to be determined. However, starting NACT more than 42 days after diagnosis of TNBC seems to reduce survival. Therefore, it is strongly recommended to carry out the treatment in a certified breast center with appropriate structures, in order to enable an adequate and timely care.